Teva Beats Q3 Estimates, Lifts 2026 Revenue and EPS Outlook
TEVA has more than doubled off its 52-week low of $19.975 on elevated volume (1.9× avg).
Summary
Teva beat Q3 expectations and raised full-year guidance, with revenue of $4.4B topping consensus by $170M and adjusted EPS of $0.86 beating by $0.14. The quarter's engine was the innovative portfolio: Austedo, Ajovy and Uzedy together added about $1.1B globally, up 33% year over year in local currency, with Ajovy up 61% and Uzedy up 96%. That offset a 16% local-currency decline in global generics, driven by lower U.S. lenalidomide (generic Revlimid) sales tied to Bristol Myers' multiple myeloma franchise. Management now sees 2026 revenue of $16.7B-$17B and adjusted EPS of $1.92-$2.11, up from $16.5B-$16.85B and $1.91-$2.11, and the biosimilar business is tracking above $800M for 2026, a year ahead of plan. Adjusted gross margin improved to 58.7% from 55.3%, a sign the mix shift toward brands is lifting profitability. The stock is trading near its 52-week high, so the guidance raise is the key test of whether the growth pivot holds.
At the time of this announcement, TEVA was trading at $41.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $47.4B. The 52-week trading range was $19.98 to $42.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.